Patents by Inventor Thomas Jorg Mehrling

Thomas Jorg Mehrling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tinostamustine for use in the treatment of T-cell prolymphocytic leukaemia
    Patent number: 11918558
    Abstract: T-PLL Therapy There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of T-cell prolymphocytic leukemia (T-PLL) in a patient in need thereof.
    Type: Grant
    Filed: April 27, 2022
    Date of Patent: March 5, 2024
    Assignee: Purdue Pharma L.P.
    Inventors: Thomas Jorg Mehrling, Marco Herling
  • Tinostamustine for use in treating ovarian cancer
    Patent number: 11896583
    Abstract: There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of ovarian cancer in a patient in need thereof.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: February 13, 2024
    Assignee: Purdue Pharma L.P.
    Inventor: Thomas Jorg Mehrling
  • Compounds for treating TNBC
    Patent number: 11786509
    Abstract: There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of triple negative breast cancer (TNBC) to a patient in need thereof.
    Type: Grant
    Filed: August 11, 2022
    Date of Patent: October 17, 2023
    Assignee: Purdue Pharma L.P.
    Inventor: Thomas Jorg Mehrling
  • COMBINATION COMPRISING A GLUCOCORTICOID AND EDO-S101
    Publication number: 20230285363
    Abstract: The present invention is directed to a combination comprising a glucocorticoid and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.
    Type: Application
    Filed: December 19, 2022
    Publication date: September 14, 2023
    Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
  • TINOSTAMUSTINE FOR USE IN TREATING SARCOMA
    Publication number: 20230277507
    Abstract: There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of sarcomain a patient in need thereof.
    Type: Application
    Filed: February 13, 2023
    Publication date: September 7, 2023
    Inventor: Thomas Jorg Mehrling
  • PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER
    Publication number: 20230241033
    Abstract: The present invention is directed to a combination comprising a proteasome inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.
    Type: Application
    Filed: December 22, 2022
    Publication date: August 3, 2023
    Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
  • COMPOUNDS FOR TREATING TNBC
    Publication number: 20230080216
    Abstract: There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of triple negative breast cancer (TNBC) to a patient in need thereof.
    Type: Application
    Filed: August 11, 2022
    Publication date: March 16, 2023
    Inventor: Thomas Jorg Mehrling
  • COMPOUNDS FOR TREATING BRAIN CANCER
    Publication number: 20230049350
    Abstract: There is provided a compound of formula I or a pharmacologically acceptable salt thereof: for use in the treatment of a brain cancer selected from a MGMT positive astrocytic brain tumour, a metastatic brain cancer and primary CNS lymphoma and a method of treating said brain cancers in a patient in need thereof comprising administering to the patient said compound of formula I or a pharmacologically acceptable salt thereof.
    Type: Application
    Filed: July 27, 2022
    Publication date: February 16, 2023
    Inventors: Thomas Jorg Mehrling, Claudio Festuccia
  • Tinostamustine for use in treating sarcoma
    Patent number: 11576899
    Abstract: There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of sarcomain a patient in need thereof.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: February 14, 2023
    Assignee: Purdue Pharma L.P.
    Inventor: Thomas Jorg Mehrling
  • Pharmaceutical combinations for treating cancer
    Patent number: 11559516
    Abstract: The present invention is directed to a combination comprising a proteasome inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: January 24, 2023
    Assignee: Purdue Pharmaceutical Products L.P.
    Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
  • Combination comprising a glucocorticoid and EDO-S101
    Patent number: 11541038
    Abstract: The present invention is directed to a combination comprising a glucocorticoid and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: January 3, 2023
    Assignee: Purdue Pharmaceutical Products L.P.
    Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
  • TINOSTAMUSTINE FOR USE IN THE TREATMENT OF T-CELL PROLYMPHOCYTIC LEUKAEMIA
    Publication number: 20220401417
    Abstract: T-PLL Therapy There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of T-cell prolymphocytic leukemia (T-PLL) in a patient in need thereof.
    Type: Application
    Filed: April 27, 2022
    Publication date: December 22, 2022
    Inventors: Thomas Jorg Mehrling, Marco Herling
  • Compounds for treating TNBC
    Patent number: 11413276
    Abstract: There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of triple negative breast cancer (TNBC) to a patient in need thereof.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: August 16, 2022
    Assignee: Purdue Pharma L.P.
    Inventor: Thomas Jorg Mehrling
  • Tinostamustine for use in the treatment of t-cell prolymphocytic leukaemia
    Patent number: 11318117
    Abstract: T-PLL Therapy There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of T-cell prolymphocytic leukemia (T-PLL) in a patient in need thereof.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: May 3, 2022
    Assignee: Purdue Pharma L.P.
    Inventors: Thomas Jorg Mehrling, Marco Herling
  • COMPOUNDS FOR TREATING MULTIPLE MYELOMA
    Publication number: 20220016085
    Abstract: The invention relates to tinostamustine for use in the treatment of multiple myeloma. Tinostamustine may cause side effects when administered to a patient, and it is desirable to minimise such effects. The present invention defines an improved treatment, wherein the dose of tinostamustine administered is varied based on the patient's platelet count.
    Type: Application
    Filed: December 18, 2019
    Publication date: January 20, 2022
    Inventors: Katarina Hilgier, Francisco Ibanez Lopez, Thomas Jorg Mehrling
  • COMPOUNDS FOR TREATING LYMPHOMA OR A T-CELL MALIGNANT DISEASE
    Publication number: 20220016084
    Abstract: The invention relates to tinostamustine for use in the treatment of lymphoma or a T-cell malignant disease. Tinostamustine may cause side effects when administered to a patient, and it is desirable to minimise such effects. The present invention defines an improved treatment, wherein the dose of tinostamustine administered is varied based on the patients platelet count.
    Type: Application
    Filed: December 18, 2019
    Publication date: January 20, 2022
    Inventors: Katarina Hilgier, Francisco Ibanez Lopez, Thomas Jorg Mehrling
  • PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER
    Publication number: 20210346351
    Abstract: The present invention is directed to a combination comprising a proteasome inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.
    Type: Application
    Filed: March 25, 2021
    Publication date: November 11, 2021
    Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
  • COMBINATION COMPRISING A GLUCOCORTICOID AND EDO-S101
    Publication number: 20210059989
    Abstract: The present invention is directed to a combination comprising a glucocorticoid and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.
    Type: Application
    Filed: August 14, 2020
    Publication date: March 4, 2021
    Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
  • TINOSTAMUSTINE FOR USE IN TREATING OVARIAN CANCER
    Publication number: 20200261423
    Abstract: There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of ovarian cancer in a patient in need thereof.
    Type: Application
    Filed: June 13, 2018
    Publication date: August 20, 2020
    Applicant: PURDUE PHARMA L.P.
    Inventor: Thomas Jorg MEHRLING
  • Combination comprising a glucocorticoid and EDO-S101
    Patent number: 10744120
    Abstract: The present invention is directed to a combination comprising a glucocorticoid and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: August 18, 2020
    Assignee: PURDUE PHARMACEUTICAL PRODUCTS L.P.
    Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio